NASDAQ:APLM
Apollomics, Inc. Stock News
$0.332
-0.0078 (-2.29%)
At Close: May 17, 2024
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
08:30am, Thursday, 25'th Apr 2024
Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gen
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
07:00am, Wednesday, 10'th Apr 2024
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR thera
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
07:00am, Thursday, 28'th Mar 2024
FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple o
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
07:00am, Monday, 04'th Mar 2024
FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07:00am, Wednesday, 07'th Feb 2024
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
04:15pm, Friday, 19'th Jan 2024
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement Apollomics has an initial 180-day period through July 15, 2024 to regain complian
Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference
04:30pm, Wednesday, 17'th Jan 2024
FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
07:00am, Wednesday, 03'rd Jan 2024
FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to addres
Apollomics to Present at the 2024 Biotech Showcase
04:30pm, Tuesday, 02'nd Jan 2024
FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
07:30am, Wednesday, 29'th Nov 2023
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
07:00am, Tuesday, 28'th Nov 2023
FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
08:30am, Thursday, 16'th Nov 2023
Apollomics' partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data ser
FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult
Why Is Apollomics (APLM) Stock Up 113% Today?
08:03am, Friday, 27'th Oct 2023
Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “efficacy response of a patient treated with vebreltinib
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
08:50am, Thursday, 26'th Oct 2023
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a pa